Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study

作者全名："Wang, Yong; Liu, Chunxiao; Liu, Chuan; Lu, Yongji; Ban, Lu; Niu, Yuanjie"

作者地址："[Wang, Yong; Niu, Yuanjie] Second Hosp Tianjin Med Univ, Dept Urol, Tianjin, Peoples R China; [Liu, Chunxiao] Southern Med Univ, Zhujiang Hosp, Dept Urol, Guangzhou, Peoples R China; [Liu, Chuan] Chongqing Med Univ, Second Affiliated Hosp, Dept Urol, Chongqing, Peoples R China; [Lu, Yongji] Astellas Pharma, Hlth Econ & Outcomes Res, Shanghai, Peoples R China; [Ban, Lu] Evidera, PPD, Beijing, Peoples R China"

通信作者："Niu, YJ (通讯作者)，Second Hosp Tianjin Med Univ, Dept Urol, Tianjin, Peoples R China."

来源：JOURNAL OF MEDICAL ECONOMICS

ESI学科分类：ECONOMICS & BUSINESS

WOS号：WOS:001183157100001

JCR分区：Q1

影响因子：2.9

年份：2024

卷号：27

期号：1

开始页：361

结束页：369

文献类型：Article

关键词：Androgen antagonists; incidence; metastatic hormone-sensitive prostate cancer; nonmetastatic castration-resistant prostate cancer; prevalence; treatment pattern; I00; I; I13; I1

摘要："AimThis study assessed the treatment patterns, healthcare resource utilization (HRU), costs, and annual prevalence and incidence of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) in China.MethodsA retrospective study was conducted using electronic medical records (EMR) of patients with prostate cancer from three tertiary-care hospitals in China between January 2014 and March 2021. Descriptive statistics were used to analyze study outcomes.ResultsIn total, 1086 patients with mHSPC and 679 patients with nmCRPC were included. From 2015 to 2020, the annual percentage of prevalent and incident cases of mHSPC decreased from 22.4% to 20.0% and 11.1% to 6.9%, respectively; for nmCRPC, these increased from 3.8% to 13.6% and 3.3% to 8.4%. Androgen-deprivation therapy and first-generation antiandrogens (bicalutamide or flutamide) were the most frequently prescribed prostate cancer-related medications at baseline and follow-up in patients with mHSPC. Bicalutamide was the most frequently prescribed prostate cancer-related medication during follow-up in patients with nmCRPC. For mHSPC, inpatient admission costs were the highest, with the median (interquartile range) costs per person-month being USD 403.00 (USD 85.50-1226.20), whereas outpatient visit costs were the highest for nmCRPC (USD 372.60 [USD 139.50-818.50]).LimitationsEMR-based study design did not capture treatment patterns, HRU and associated costs, and healthcare encounters that occurred outside of participating hospitals, which could have led to underestimation of the true disease burden.ConclusionsA contrasting trend of a decline in the prevalence and incidence of mHSPC and an increase in these for nmCRPC was observed between 2015 and 2020 in China. Androgen-deprivation therapy and first-generation antiandrogens were the most frequently prescribed prostate cancer-related medications. Healthcare resource utilization was driven by inpatient costs in mHSPC and outpatient costs in nmCRPC."

基金机构：Astellas Pharma Inc.

基金资助正文："The authors would like to thank Leena Patel, Chrysi Petraki, and Rucha Kurtkoti from IQVIA for medical writing and editorial support."